Ranibizumab
- Generic Name
- Ranibizumab
- Brand Names
- Byooviz, Cimerli, Lucentis, Susvimo, Ranivisio, Rimmyrah, Ximluci
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 347396-82-1
- Unique Ingredient Identifier
- ZL1R02VT79
- Background
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration. Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovasc...
- Indication
Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
...
- Associated Conditions
- Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD)
- Associated Therapies
- -
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 25
- Registration Number
- NCT02181517
A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.
- Conditions
- Interventions
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- King's College Hospital NHS Trust
- Target Recruit Count
- 59
- Registration Number
- NCT02174211
- Locations
- 🇬🇧
King's College Hospital NHS Foundation Trust, London, UK, United Kingdom
Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion
- Conditions
- Interventions
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2014-06-23
- Lead Sponsor
- Tokyo Medical University
- Target Recruit Count
- 100
- Registration Number
- NCT02169648
- Locations
- 🇯🇵
Hachioji Medical Center, Tokyo Medical University, Tokyo, Japan
Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD
- Conditions
- Interventions
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 103
- Registration Number
- NCT02161575
- Locations
- 🇬🇧
Novartis Investigative Site, York, United Kingdom
Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2017-08-25
- Lead Sponsor
- St. Marianna University School of Medicine
- Target Recruit Count
- 50
- Registration Number
- NCT02144662
Combination Treatment of Intravitreal Ranibizumab, Focal/Grid Laser and Panretinal Photocoagulation in Patients With Diabetic Macula Edema
- Conditions
- Interventions
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Shinshu University
- Target Recruit Count
- 40
- Registration Number
- NCT02131350
- Locations
- 🇯🇵
Department ou Ophthalmology Shinshu University School of Medicine, Matsumoto, Nagano, Japan
Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- Maturi, Raj K., M.D., P.C.
- Registration Number
- NCT02127684
- Locations
- 🇺🇸
Raj K Maturi MD, Indianapolis, Indiana, United States
Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- California Retina Consultants
- Target Recruit Count
- 56
- Registration Number
- NCT02118831
Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Mie University
- Target Recruit Count
- 30
- Registration Number
- NCT02091505
- Locations
- 🇯🇵
Mie University Hospital, Tsu, Aichi, Japan
Analysis of Aqueous and Vitreous Humor
- First Posted Date
- 2014-02-20
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- California Retina Consultants
- Target Recruit Count
- 45
- Registration Number
- NCT02067013
- Locations
- 🇺🇸
California Retina Consultants - Santa Barbara Office, Santa Barbara, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.